BeiGene upgraded to Buy ahead of expected Chinese approvals at CLSA
CLSA upgraded BeiGene to Buy from Outperform as they see manufacturing approval of two drug candidates – Zanubrutinib and Tislelizumab – in China as the next catalyst for the shares. The firm keeps a HK$96.52 price target on BeiGene shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.